Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.
Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to ...
The updated Covid-19 vaccine approvals follow the June FDA's Vaccines and Related Biological Products Advisory Committee ...
Sanofi, RadioMedix and Orano Med have entered into an exclusive licensing agreement worth €320m to develop a next-generation ...
Gaithersburg, Maryland-based Novavax received ... it struck a $1.2 billion licensing agreement with French drugmaker Sanofi to co-commercialize the combination vaccine. Get breaking news and ...
PR Newswire • 16 days ago Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized ... Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Stresses Significant Value ...
Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to develop ...
Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry. Novavax stock ...
Deal focuses on AlphaMedix cancer treatment project (Il Sole 24 Ore Radiocor) - Paris , 12 Sep - French pharmaceutical company Sanofi said it has entered into an exclusive licensing agreement with ...
Health Canada authorized Novavax’s updated COVID-19 vaccine that protects against currently circulating variants of the virus on Thursday. The protein-based vaccine, called Nuvaxovid ...